210 related articles for article (PubMed ID: 8866312)
1. Plasminogen activator activity is decreased in rat gingiva during diabetes.
Chang K; Rani AS; Chang K; Kumar S
J Periodontol; 1996 Aug; 67(8):743-47. PubMed ID: 8866312
[TBL] [Abstract][Full Text] [Related]
2. Local and systemic factors in periodontal disease increase matrix-degrading enzyme activities in rat gingiva: effect of micocycline therapy.
Chang KM; Ryan ME; Golub LM; Ramamurthy NS; McNamara TF
Res Commun Mol Pathol Pharmacol; 1996 Mar; 91(3):303-18. PubMed ID: 8829770
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts.
Xiao Y; Bunn CL; Bartold PM
J Periodontal Res; 1998 Jan; 33(1):17-26. PubMed ID: 9524317
[TBL] [Abstract][Full Text] [Related]
4. The expression of plasminogen activator system in a rat model of periodontal wound healing.
Xiao Y; Li H; Bunn C; Bartold PM
J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131
[TBL] [Abstract][Full Text] [Related]
5. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
Wilson MJ; Ludowese C; Sinha AA; Estensen RD
Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
[TBL] [Abstract][Full Text] [Related]
6. Chemically-modified tetracycline normalizes collagen metabolism in diabetic rats: a dose-response study.
Yu Z; Ramamurthy NS; Leung M; Chang KM; McNamara TF; Golub LM
J Periodontal Res; 1993 Nov; 28(6 Pt 1):420-8. PubMed ID: 8254459
[TBL] [Abstract][Full Text] [Related]
7. Diabetes prevents periodontitis-induced increases in gingival platelet derived growth factor-B and interleukin 1-beta in a rat model.
Doxey DL; Cutler CW; Iacopino AM
J Periodontol; 1998 Feb; 69(2):113-9. PubMed ID: 9526909
[TBL] [Abstract][Full Text] [Related]
8. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
9. Assay method for single-chain urokinase-type plasminogen activator.
Matsuo O; Ueshima S; Okada K; Fukao H; Ohgaki M; Watanabe R; Arimura H
Hematol Pathol; 1989; 3(3):137-42. PubMed ID: 2531734
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
11. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models.
Hagiwara H; Kaizu K; Uriu K; Noguchi T; Takagi I; Qie YL; Seki T; Ariga T
Thromb Res; 2003; 111(4-5):301-9. PubMed ID: 14693179
[TBL] [Abstract][Full Text] [Related]
12. A clinical study of plasminogen activator activity in gingival tissue in dogs with gingivitis and periodontitis.
Papadimitriou S; Tsantarliotou M; Makris G; Papaioannou N; Batzios Ch; Kokolis N; Dessiris A
Res Vet Sci; 2006 Apr; 80(2):189-93. PubMed ID: 16098551
[TBL] [Abstract][Full Text] [Related]
13. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
14. Reductions in mRNA of the neuroprotective agent, neuroserpin, after cerebral ischemia/reperfusion in diabetic rats.
Liang W; Chuan-Zhen L; Qiang D; Jian Q; Hui-Min R; Bao-Guo X
Brain Res; 2004 Jul; 1015(1-2):175-80. PubMed ID: 15223382
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
16. Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways.
Milner JM; Elliott SF; Cawston TE
Arthritis Rheum; 2001 Sep; 44(9):2084-96. PubMed ID: 11592371
[TBL] [Abstract][Full Text] [Related]
17. Functional assay of plasminogen activator by hydrolysis of 14C-globin.
Finci Z; Nachshon I; Sharoni Y; Mayer M
Exp Hematol; 1986 May; 14(4):293-7. PubMed ID: 2938980
[TBL] [Abstract][Full Text] [Related]
18. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
Buduneli N; Buduneli E; Ciotanar S; Atilla G; Lappin D; Kinane D
J Clin Periodontol; 2004 Jul; 31(7):556-61. PubMed ID: 15191592
[TBL] [Abstract][Full Text] [Related]
20. Membrane-associated procollagenase of leukemic cells is activated by urokinase-type plasminogen activator.
Santibañez JF; Martínez J
Leuk Res; 1993 Dec; 17(12):1057-62. PubMed ID: 8246609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
